# Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer

> **NCT05215379** · PHASE2,PHASE3 · COMPLETED · sponsor: **Changhai Hospital** · enrollment: 201 (actual)

## Conditions studied

- Neoadjuvant Chemoradiation Therapy
- Rectal Cancer
- Immunotherapy
- Microsatellite Instability Low

## Interventions

- **DRUG:** xintilimab injection
- **OTHER:** Control

## Key facts

- **NCT ID:** NCT05215379
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-06-24
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05215379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05215379, "Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05215379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*